HONG KONG –MSD China Holding Co. Ltd. (known as Merck & Co. Inc. in the U.S. and Canada) received approval for Keytruda (pembrolizumab) in China, making it the second PD-1 inhibitor drug approved in the country after Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and the first one for advanced melanoma.